Kidney Cancer Biomarker Selection Using Regularized Survival Models

Cells. 2022 Jul 27;11(15):2311. doi: 10.3390/cells11152311.

Abstract

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of RCC showing a significant percentage of mortality. One of the priorities of kidney cancer research is to identify RCC-specific biomarkers for early detection and screening of the disease. With the development of high-throughput technology, it is now possible to measure the expression levels of thousands of genes in parallel and assess the molecular profile of individual tumors. Studying the relationship between gene expression and survival outcome has been widely used to find genes associated with cancer survival, providing new information for clinical decision-making. One of the challenges of using transcriptomics data is their high dimensionality which can lead to instability in the selection of gene signatures. Here we identify potential prognostic biomarkers correlated to the survival outcome of ccRCC patients using two network-based regularizers (EN and TCox) applied to Cox models. Some genes always selected by each method were found (COPS7B, DONSON, GTF2E2, HAUS8, PRH2, and ZNF18) with known roles in cancer formation and progression. Afterward, different lists of genes ranked based on distinct metrics (logFC of DEGs or β coefficients of regression) were analyzed using GSEA to try to find over- or under-represented mechanisms and pathways. Some ontologies were found in common between the gene sets tested, such as nuclear division, microtubule and tubulin binding, and plasma membrane and chromosome regions. Additionally, genes that were more involved in these ontologies and genes selected by the regularizers were used to create a new gene set where we applied the Cox regression model. With this smaller gene set, we were able to significantly split patients into high/low risk groups showing the importance of studying these genes as potential prognostic factors to help clinicians better identify and monitor patients with ccRCC.

Keywords: Cox regression; biomarker selection; gene ontology; kidney cancer; regularization.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism
  • Carcinoma, Renal Cell* / metabolism
  • Humans
  • Kidney / pathology
  • Kidney Neoplasms* / genetics
  • Kidney Neoplasms* / pathology
  • Transcriptome / genetics

Substances

  • Biomarkers, Tumor

Grants and funding

This research was funded by national funds through Fundação para a Ciência e a Tecnologia (FCT) with references PD/BD/139146/2018, UIDB/50021/2020 (INESC-ID), and projects MATISSE (DSAIPA/DS/0026/2019) and MONET (PTDC/CCI-BIO/4180/2020). This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 951970 (OLISSIPO project).